NEWS
Vitalea Science and Accium BioSciences Announce Initiation of Two-Way Cooperative Agreement to Cross-Validate Accelerator Mass Spectrometer (AMS) Resources
March 8, 2012
Vitalea Science and Accium BioSciences, leading providers of bioanalytical contract services based on Accelerator Mass Spectrometry (AMS), have entered a cooperative agreement to provide expanded capacity and redundancy to address continued demand from US and International clients.
Vitalea Science and Accium BioSciences, leading providers of bioanalytical contract services based on Accelerator Mass Spectrometry (AMS), are pleased to announce the initiation of a cooperative agreement and launch of a series of internal studies to cross-validate each other’s AMS platform. Successful completion of these studies will permit delivery of bioanalytical services supported by backup AMS instrumentation operating under a unified and validated framework. Pharmaceutical companies may continue to request the services of either Vitalea or Accium with the added reassurance of backup measurement capacity, instrument redundancy and highest quality standards.
AMS is an ultrasensitive detection platform that often complements other tools available to the bioanalytical scientist. Notably, AMS provides proven solutions for quantifying the pharmacokinetics and metabolism of drug candidates in humans, both prior to and as part of Phase 1 clinical trials. AMS also offers specific advantages in preclinical models and in the development of biologic-based therapeutics.
“Capacity and the ability to consistently meet our Sponsor’s timelines are key factors in securing and maintaining business,” commented Bob Bethem, Chief Executive Officer at Vitalea. “Accium and Vitalea will continue to compete for AMS studies worldwide but our labs share a common guiding principle to shape our AMS services according to industry expectations. We will continue to provide the highest level of study design and execution at Vitalea with the added reassurance of this new backup contingency plan.”
“We are excited to embark on these cross-validation studies and offer expanded capacity and redundancy to new and existing clients,” said Ali Arjomand, President and Chief Operating Officer at Accium. “Vitalea's co-founder, Stephen Dueker, and I have a scientific relationship that dates back to the pioneering days of biomedical AMS research at the University of California and Lawrence Livermore National Laboratory in the mid-1990s. The cooperative agreement announced here will bridge the AMS resources and technical expertise of both companies and provide greater value to pharmaceutical sponsors and the AMS community at large.”
Previously, the two companies independently performed bioanalytical procedures and AMS measurement of samples generated in a sponsored study. The results demonstrated “acceptable accuracy & precision of the AMS measurements at both labs via the use of QC samples. Dog plasma samples measured by the two AMS labs were comparable to each other and were similar to values obtained by LC-MS/MS.” Vitalea and Accium are excited to build on that success by completing cross-validation studies that will expand instrument capacity and redundancy at both facilities. See Press Release
Accium and Swedish Medical Center Launch a Clinical Trial in Patients with Newly Diagnosed Glioblastoma Multiforme: Novel AMS Study for the Quantitation of Tumor 14C-Temozolomide Uptake
September 21, 2011
We are pleased to announce the initiation of an internal clinical study to quantify tumor uptake of 14C-Temozolomide (Temodar) and subsequent 14C-methylation of tumor DNA. The primary objective of the study is to evaluate a series of pharmacologic endpoints (biomarkers) as predictors of Temozolomide efficacy in individual patients. Predictive biomarkers, also known as companion diagnostic tests, help to identify the right treatment for each patient and may help improve overall outcome. Our neurosurgeon collaborator, Dr. Greg Foltz at Swedish Neuroscience Institute in Seattle, is providing surgical expertise and patient care at the Swedish Medical Center located adjacent to Accium's AMS facility.
Accium BioSciences Announces $99 Sample Pricing for Its Accelerator Mass Spectrometry (AMS) Measurement Service
October 19, 2010
Accium BioSciences, a leading provider of bioanalytical accelerator mass spectrometry (AMS) services in North America, announced today new pricing for its AMS measurement service at $99 per sample. GLP-compliant service is now available at $115 per sample. The new pricing includes sample graphitization and AMS measurement services. Accium will continue to provide expert bioanalytical and quality assurance services at competitive rates.
Accium BioSciences listed in 25 Startups Revolutionizing Biotechnology
June 4, 2010
"This company is leading the way in commercial uses for Accelerator Mass Spectrometry (AMS) in North America. AMS techniques from Accium BioSciences can be used in bioanalysis, offering super sensitive methods of quantitation. These techniques can be used in the early stages of drug development. The equipment and techniques can be used to help boost patient safety, as well as reduce failure in clinical trials. Hopefully, the AMS technique can be used to reduce costs."
J. Scott Tarrant Joins Accium BioSciences as Vice President of Corporate Development
August 1, 2009
Accium BioSciences is pleased to announce the addition of J. Scott Tarrant as the company's Vice President of Corporate Development. Most recently Scott served as Executive Vice President of Global Sales and Marketing for UK based Xceleron Ltd, a specialty CRO utilizing accelerator mass spectrometry (AMS) to obtain early ADME and PK data in exploratory clinical development. In his new role at Accium, Scott will drive the company's efforts to bring AMS-based services to the broader early phase drug development market while the company continues its commitment to the highest standards of quality and value.
Scott’s addition is part of a six month growth effort at Accium BioSciences aimed at delivering expanded service capability, increased sample capacity, faster turnaround and higher quality. We recently announced the addition of a second and larger ion source to our AMS instrument which increases the measurement capacity of the instrument. We also implemented an improved sample tracking and documentation system which has already resulted in speedier QA review and release of Final Reports.
Accium BioSciences is expanding its operations!!
May 1, 2009
Accium BioSciences is expanding its AMS service operations by implementing a new sample documentation system and a large-capacity sample injector for its AMS instrument.
- A new sample documentation, sample tracking and chain-of-custody system has been implemented at Accium. The new system provides much more efficient documentation of sample preparation and tracking and improves productivity and turnaround-time for each study.
- Accium's AMS instrument will be upgraded in July 2009 with the addition of a new sample injector ion source. Running in conjunction with the existing 40-sample injector, the new 134-sample injector will increase throughput and measurement capacity by at least three-fold. This means more data points will be generated in a 24-hour period, helping to speed study turnaround time and overall service capacity!
Accium BioSciences, Pioneer of Particle Accelerator for Drug Development, Finds Niche Xconomy
October 21, 2008
Accium Announces Publication in RADIOCARBON titled "Performance Evaluation of New Accelerator Mass Spectrometer at Accium BioSciences"
May 20, 2007
Analytical Bio-Chemistry Laboratories and Accium BioSciences Announce a Partnership to Offer Microdosing and Low Radiation Services
February 26, 2007
Accium BioSciences and CMIC Announce Strategic Alliance to Provide Exploratory IND and Low-Radiation PK/ADME Services to the Japanese Pharmaceutical Industry
October 19, 2006
Accium BioSciences and Quintiles Transnational Corporation Establish Strategic Partnership for Microdosing and Information-Rich™ Phase I Trials
May 23, 2006
Battelle, BattelleCRO, and Accium Biosciences Form Collaboration to Speed Product Development Cycle
May 23, 2006
Accium BioSciences Finances Microdosing Operation, Brings on Key Personnel
January 5, 2006
Accium BioSciences and Radiant Research Forge Strategic Co-Marketing Agreement
June 15, 2005
